| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.145.3638.1310 |
| P698 | PubMed publication ID | 14173416 |
| P2093 | author name string | RATNOFF OD | |
| DAVIE EW | |||
| P433 | issue | 3638 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1310-1312 | |
| P577 | publication date | 1964-09-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. | |
| P478 | volume | 145 |
| Q35564946 | A brief historical review of the waterfall/cascade of blood coagulation |
| Q35617165 | A cell-based model of coagulation and the role of factor VIIa |
| Q33305460 | A coagulation factor becomes useful in the study of acute leukemias: studies with blood coagulation factor XIII. |
| Q36663924 | A new look at prosthetic materials |
| Q78673290 | A novel prothrombin activator from the venom of Micropechis ikaheka: isolation and characterization |
| Q39539762 | A plasma proteolysis pathway comprising blood coagulation proteases |
| Q35844915 | Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia |
| Q35148665 | Actions and Interactions of Antithrombin and Heparin |
| Q33927262 | Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. |
| Q42601092 | Activated plasma coagulation β-Factor XII-induced vasoconstriction in rats |
| Q40582622 | Activation markers of coagulation |
| Q72637975 | Activation of hageman factor by sodium urate crystals |
| Q52859484 | Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin |
| Q33793626 | Activation of the plasma kallikrein/kinin system on endothelial cell membranes |
| Q38711786 | An Insight into the Triabin Protein Family of American Hematophagous Reduviids: Functional, Structural and Phylogenetic Analysis |
| Q34172057 | An allosteric switch controls the procoagulant and anticoagulant activities of thrombin |
| Q43678212 | An approach to the evaluation of hemostasis |
| Q37685042 | An endothelial cell-dependent pathway of coagulation |
| Q39636448 | An overview of hemostasis |
| Q40766785 | An overview of hemostasis |
| Q47311661 | An update on factor XI structure and function |
| Q39885455 | Anticoagulant and thrombolytic drugs. I. Patho-physiological and pharmacological aspects |
| Q71116206 | Anticoagulant effects of Trasylol: in vitro and in vivo studies |
| Q41101978 | Antithrombin III in fresh and cultured human endothelial cells: A natural anticoagulant from the vascular endothelium |
| Q35064114 | Approach to the bleeding child |
| Q36228361 | Are hemostasis and thrombosis two sides of the same coin? |
| Q35546879 | Arterial thrombosis for the interventional cardiologist: From adhesion molecules and coagulation factors to clinical therapeutics |
| Q37897474 | Arterial thrombus formation in cardiovascular disease |
| Q92508117 | Automated reduction of blood coagulation models |
| Q33348055 | Barnacle cement: a polymerization model based on evolutionary concepts |
| Q35539943 | Beneficial effects of metformin on haemostasis and vascular function in man. |
| Q60077877 | Big rigs in blood coagulation |
| Q63246719 | BioBits™ Explorer: A modular synthetic biology education kit |
| Q71846063 | Biological Properties of the Naturally Occurring Plasma Inhibitor to Activated Factor X |
| Q47324534 | Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding. |
| Q42180318 | Biomimetic reliability strategies for self-healing vascular networks in engineering materials. |
| Q45858588 | Blood coagulation and hemophilioid disorders |
| Q33606686 | Blood coagulation and its alterations in hemorrhagic and thrombotic disorders |
| Q37930460 | Blood coagulation factor XII--a neglected player in stroke pathophysiology |
| Q41905355 | Blood coagulation induced by Iranian saw-scaled viper (echis carinatus) venom: identification, purification and characterization of a prothrombin activator |
| Q70931052 | Blood-compatible plastics |
| Q39491826 | By what mechanisms could prothrombin complex concentrates promote factor VIII bypassing activity in vivo? |
| Q39392693 | COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke |
| Q34211617 | Carboxypeptidase U at the interface between coagulation and fibrinolysis |
| Q36920715 | Causes and consequences of critical bleeding and mechanisms of blood coagulation |
| Q35542199 | Changes in haemostasis during normal pregnancy: does homocysteine play a role in maintaining homeostasis? |
| Q73953674 | Channeling during prothrombin activation |
| Q38879831 | Characterization of distinct coagulopathic phenotypes in injury: Pathway-specific drivers and implications for individualized treatment |
| Q40303583 | Clinical evaluation of the patient with bruising and bleeding |
| Q35672990 | Clinical practice: the bleeding child. Part II: disorders of secondary hemostasis and fibrinolysis |
| Q64093592 | Coagulation Pathways in Neurological Diseases: Multiple Sclerosis |
| Q42407525 | Coagulation and fibrinolysis after injury |
| Q33378387 | Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass |
| Q37781402 | Coagulation factor XI as a novel target for antithrombotic treatment. |
| Q39779330 | Coagulation for cardiologists |
| Q35775912 | Coagulation in sepsis |
| Q39554592 | Coagulation monitoring in the surgical intensive care unit. |
| Q26766108 | Coagulopathy and transfusion therapy in pediatric liver transplantation |
| Q35926044 | Comparative aspects of blood coagulation |
| Q27027361 | Complement-Coagulation Cross-Talk: A Potential Mediator of the Physiological Activation of Complement by Low pH |
| Q70514695 | Conversion of bovine prekallikrein to kallikrein. Evidence of limited proteolysis of prekallikrein by bovine hageman factor (factor XII) |
| Q33401040 | Correction of coagulopathy for percutaneous interventions |
| Q27679142 | Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis |
| Q24646366 | Defective thrombus formation in mice lacking coagulation factor XII |
| Q33473978 | Defibrination syndrome in a patient with chronic thrombocytopenic purpura |
| Q36176667 | Design and characterization of an APC-specific serpin for the treatment of hemophilia. |
| Q36507116 | Determination of FVIIa-sTF Inhibitors in Toxic Microcystis Cyanobacteria by LC-MS Technique |
| Q37646551 | Developments in factor Xa inhibitors for the treatment of thromboembolic disorders |
| Q87104839 | Diagnosis and management of disseminated intravascular coagulation |
| Q36715734 | Diagnostic approach to inherited bleeding disorders |
| Q55399338 | Diffuse intravascular clotting associated with a primary brain tumour. |
| Q35177353 | Discovery methodology for the development of direct factor VIIa inhibitors. |
| Q88007875 | Dispelling myths about coagulation abnormalities in internal medicine |
| Q68917496 | Disseminated intravascular coagulation |
| Q38578543 | Dosing of rivaroxaban by indication: getting the right dose for the patient. |
| Q82358510 | Effects of intravenous aminocaproic acid on exercise‐induced pulmonary haemorrhage (EIPH) |
| Q40177731 | Endothelial cell culture: beginnings of modern vascular biology |
| Q37332176 | Endothelial cell fibrinolytic assembly |
| Q42212287 | Enzymology and blood coagulation |
| Q46894803 | Epinephrine: cascade reactions and glycogenolytic effect |
| Q33374743 | Essentials of anticoagulation in hemodialysis |
| Q72223034 | Esterase and Clotting Activities Derived from Citrate Activation of Human Prothrombin |
| Q33743433 | Evaluation of anticoagulants for serologic assays of cholera vaccination |
| Q46506868 | Evaluation of the bleeding patient |
| Q45863678 | Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficiency |
| Q37626463 | Evidence for factor IX-independent roles for factor XIa in blood coagulation. |
| Q37778291 | Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. |
| Q36516970 | Exploring Staphylococcus aureus pathways to disease for vaccine development. |
| Q45880299 | Expression of blood clotting factor VIII:C gene in capillary endothelial cells |
| Q30479254 | Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation |
| Q41661951 | FVIIa-sTF and Thrombin Inhibitory Activities of Compounds Isolated from Microcystis aeruginosa K-139. |
| Q34500136 | Factor XI activation in a revised model of blood coagulation |
| Q37897854 | Factor XI and XII as antithrombotic targets |
| Q35501492 | Factor XII gene mutation in the Hageman family |
| Q37636983 | Factor XII inhibition reduces thrombus formation in a primate thrombosis model |
| Q33931725 | Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis |
| Q24602015 | Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis |
| Q37303864 | Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein |
| Q36704975 | Familial venous thrombosis |
| Q37950860 | Fibrinogen as a key regulator of inflammation in disease |
| Q59060846 | Formation of Prothrombin Converting Activity |
| Q33698712 | Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin |
| Q54590791 | Formation of intrinsic factor-X activator activity, with special reference to the role of thrombin. |
| Q33585242 | Genetics of human blood coagulation |
| Q27680808 | GpIbα Interacts Exclusively with Exosite II of Thrombin |
| Q78389805 | HUMAN PLATELET LIPIDS AND THEIR RELATIONSHIP TO BLOOD COAGULATION |
| Q28748668 | Hageman factor, platelets and polyphosphates: early history and recent connection |
| Q37874480 | Hemoconcentration and hemostasis during acute stress: interacting and independent effects |
| Q37903961 | Historical perspective and future direction of coagulation research |
| Q37903963 | Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin |
| Q35001654 | History of pediatric hematology oncology |
| Q34022469 | History of tissue factor |
| Q46043710 | Host-guest composites for induced hemostasis and therapeutic healing in traumatic injuries |
| Q38602890 | How to use D-dimer in acute cardiovascular care |
| Q36998879 | Human plasma kallikrein-kinin system: physiological and biochemical parameters |
| Q55261637 | Identification of serpins specific for activated protein C using a lysate-based screening assay. |
| Q71838452 | Immediate effect of components from the interior of human cells on blood coagulation |
| Q72958166 | Immediate effect of subcellular components of human cells on blood coagulation |
| Q37690716 | Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex |
| Q36735417 | In search of partners: linking extracellular proteases to substrates |
| Q35038341 | In vitro and in vivo correlation of clotting protease activity: Effect of heparin |
| Q50130999 | Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces |
| Q47830086 | Inhibition of normal clotting and Fletcher factor activity by rabbit anti-kallikrein antiserum. |
| Q36022738 | Interactions between coagulation and complement--their role in inflammation |
| Q89576223 | Interactions of viruses and the humoral innate immune response |
| Q45879003 | Investigation of adverse effects of interactions between herbal drugs and natural blood clotting mechanism |
| Q37402410 | Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis |
| Q36008892 | Is there value in kinetic modeling of thrombin generation? Yes. |
| Q33802149 | Kinetics of recombinant adeno-associated virus-mediated gene transfer |
| Q39981086 | Laboratory Aids in the Recognition of Bleeding Disorders |
| Q72625638 | Laboratory aspects of immune deficiency in children |
| Q39882443 | Laboratory tests for the assessment of nutritional status |
| Q46749734 | Leptospira interrogans reduces fibrin clot formation by modulating human thrombin activity via exosite I. |
| Q38627278 | Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation |
| Q39991631 | Local and systemic factors in the pathogenesis of thrombosis |
| Q33851506 | Longistatin, a plasminogen activator, is key to the availability of blood-meals for ixodid ticks |
| Q39797855 | Low-dose heparin: Is the risk worth the benefit? |
| Q36651166 | Management of coagulopathy in the setting of acute neurosurgical disease and injury |
| Q36269052 | Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro |
| Q51423259 | Mechanisms of peptide hydrolysis by aspartyl and metalloproteases. |
| Q39974731 | Mechanisms of thrombosis |
| Q70410731 | Mechanisms of thrombus formation and lysis |
| Q36284640 | Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma |
| Q41316755 | Membrane Interaction of the Factor VIIIa Discoidin Domains in Atomistic Detail |
| Q39770485 | Membrane and lipid involvement in blood coagulation |
| Q35801753 | Modeling Disorders of Blood Coagulation in the Zebrafish |
| Q42936605 | Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin |
| Q71426909 | Molecular Forms of Antihaemophilic Globulin in Plasma, Cryoprecipitate and after Thrombin Activation |
| Q27659000 | Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex |
| Q45856964 | Molecular deficiencies of human blood coagulation |
| Q38079153 | Monitoring target specific anticoagulants. |
| Q35309290 | Mutant defective in processing of an enzyme located in the lysosome-like vacuole of Saccharomyces cerevisiae |
| Q34069668 | NMR resonance assignments of thrombin reveal the conformational and dynamic effects of ligation. |
| Q37563464 | NMR reveals a dynamic allosteric pathway in thrombin. |
| Q28539127 | Network analyses reveal pervasive functional regulation between proteases in the human protease web |
| Q40219568 | New methods in coagulation |
| Q35477740 | Non-tissue factor procoagulants in cancer cells |
| Q36058696 | Normal and abnormal hemostasis--an integrated view. A review |
| Q27023547 | On the origin of microparticles: From "platelet dust" to mediators of intercellular communication |
| Q72058071 | On the treatment of Factor II, VII and X deficiency with P.P.S.B |
| Q34211321 | Our ancient heritage in blood clotting and some of its consequences |
| Q89868217 | Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation |
| Q36078257 | Participation of components of the blood coagulation system in the inflammatory response |
| Q40864217 | Past and Present Views of Inflammation |
| Q38380461 | Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. |
| Q37520011 | Physiological responses to protein aggregates: fibrinolysis, coagulation and inflammation (new roles for old factors). |
| Q70943117 | Physiology of blood coagulation: Advances, problems and present status |
| Q53839246 | Platelet lipids and coagulation in plasma. II. Thromboplastic activity. |
| Q34599754 | Platelet polyphosphate: an endogenous activator of coagulation factor XII |
| Q35631344 | Polyphosphate is a cofactor for the activation of factor XI by thrombin |
| Q38096457 | Practical coagulation for the blood banker |
| Q34052471 | Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation |
| Q26852301 | Protease signalling: the cutting edge |
| Q57531335 | Protease-Activatable Scaffold Proteins as Versatile Molecular Hubs in Synthetic Signaling Networks |
| Q24310133 | Protein S binds to and inhibits factor Xa |
| Q37024500 | Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. |
| Q38966192 | Proteinases, Their Extracellular Targets, and Inflammatory Signaling. |
| Q50961053 | Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation. |
| Q37251595 | Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for serine hydrolase inhibition |
| Q42247503 | Proteomics approach to the study of cattle tick adaptation to white tailed deer |
| Q24675072 | Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions |
| Q35879063 | Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential |
| Q35852300 | Recombinant biologics for treatment of bleeding disorders |
| Q36892185 | Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent |
| Q35004987 | Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor |
| Q34294608 | Remodeling the blood coagulation cascade |
| Q39912853 | Research on Haemostasis: Some Urgent Questions |
| Q33393140 | Review of continuing education course on hemostasis |
| Q34644690 | Role of Factor XII in hemostasis and thrombosis: clinical implications |
| Q39749132 | Role of platelet activation and fibrin formation in thrombogenesis |
| Q33848859 | Role of proteolytic enzymes in biological regulation (a review) |
| Q71429844 | Role of surface charge of the blood vessel wall, blood cells, and prosthetic materials in intravascular thrombosis |
| Q71449840 | Screening tests in hemostasis |
| Q39948297 | Selected topics on blood coagulation |
| Q40470385 | Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. |
| Q47900623 | Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex |
| Q35160253 | Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery |
| Q57074097 | Self-Healing Materials via Reversible Crosslinking of Poly(ethylene oxide)-Block-Poly(furfuryl glycidyl ether) (PEO-b-PFGE) Block Copolymer Films |
| Q58964468 | Sequence Theories of Blood Coagulation re-evaluated with reference to Lipid–Protein Interactions |
| Q34419933 | Shear-thinning nanocomposite hydrogels for the treatment of hemorrhage |
| Q57526897 | Solution conformation of α, β or γ-methylglutamyl-containing derivatives as probes of vitamin K-dependent carboxylase using molecular modelling and nuclear magnetic resonance |
| Q30476822 | Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively |
| Q38530486 | Structural transitions during prothrombin activation: On the importance of fragment 2 |
| Q39263299 | Studies on the formation of the prothrombin-converting complex |
| Q40173311 | Surface-governed molecular regulation of blood coagulation |
| Q45796226 | Systems of Zymogen Activation **. |
| Q52338988 | TAILS N-Terminomics and proteomics reveal complex regulation of proteolytic cleavage by O-glycosylation. |
| Q36015513 | THE ELECTROCHEMICAL PRECIPITATION OF FIBRINOGEN. |
| Q33924617 | Taking the thrombin "fork". |
| Q36580126 | Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant |
| Q28508572 | Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis |
| Q42712249 | Targeting proteases in atherosclerosis: hitting the nail with the hammer |
| Q34563752 | Targeting proteases: successes, failures and future prospects |
| Q41171782 | The Effects of the Contact Activation System on Hemorrhage |
| Q41017016 | The Formation of Microthrombi in Parenchymal Microvessels after Traumatic Brain Injury Is Independent of Coagulation Factor XI. |
| Q40167399 | The Genetics of Blood Coagulation |
| Q39922946 | The Genetics of Hereditary Disorders of Blood Coagulation |
| Q72520717 | The Inhibition of Activated Factor X with Di:isopropyl Fluorophosphate |
| Q38956551 | The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy |
| Q39912861 | The Normal Coagulation Mechanism |
| Q38897750 | The Pathogenetic Role of Apoptosis in Hypercoagulable States |
| Q71492170 | The Relation of ‘Fletcher Factor’ to Factors XI and XII |
| Q34076628 | The Role of Proaccelerin in Human Blood Coagulation. Evidence that Proaccelerin Is Converted to a Prothrombin-converting Principle by Activated Stuart Factor: With Notes on the Anticoagulant Action of Soybean Trypsin Inhibitor, Protamine Sulfate, an |
| Q39784389 | The Role of Serine Proteases in the Blood Coagulation Cascade |
| Q34458071 | The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. |
| Q61405248 | The action of high-dose factor Vlla (FVIIa) in a cell-based model of hemostasis |
| Q33901363 | The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor |
| Q40118397 | The biochemistry of coagulation. |
| Q38632499 | The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities |
| Q28679165 | The current status of coagulation |
| Q36833564 | The dimeric structure of factor XI and zymogen activation |
| Q30155268 | The dynamic structure of thrombin in solution |
| Q72183330 | The effect of materials on the later stages of thein vitro clotting of human plasma in relation to the development of vascular prostheses |
| Q36841363 | The elusive physiologic role of Factor XII |
| Q35655139 | The events that lead to thrombosis |
| Q40192020 | The extrinsic system. |
| Q41012475 | The identification and localization of antithrombin III in human tissues |
| Q70499897 | The intrinsic activation of factor x in blood coagulation |
| Q37853060 | The many faces of the contact pathway and their role in thrombosis |
| Q38737709 | The molecular biology and biochemistry of tissue factor |
| Q40817282 | The pathologist as a clinical consultant for hemostasis in the community hospital. |
| Q26995817 | The pharmacological landscape and therapeutic potential of serine hydrolases |
| Q66953270 | The quantitation of rat serum esterases by densitometry of acrylamide gels stained for enzyme activity |
| Q57816367 | The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A |
| Q72388599 | The role of heparin in intrinsic blood coagulation |
| Q57170189 | The role of neutrophils in thrombosis |
| Q27648918 | The tertiary structure and domain organization of coagulation factor VIII |
| Q36809566 | Theories of blood coagulation |
| Q37379818 | Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. |
| Q45130928 | Thrombin as important factor for cutaneous wound healing: comparison of fibrin biomatrices in vitro and in a rat excisional wound healing model. |
| Q37900072 | Thrombin generation in hemorrhage control and vascular occlusion |
| Q33640335 | Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke |
| Q40043008 | Thrombophlebitis and Basic Vascular Problems |
| Q40938710 | Thrombosis and the pharmacology of antithrombotic agents |
| Q53691746 | Thrombosis in Cerebral Aneurysms and the Computational Modeling Thereof: A Review. |
| Q36403196 | Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein |
| Q35750758 | Tissue factor and tissue factor pathway inhibitor |
| Q47772655 | Tissue factor pathway inhibitor endocytosis |
| Q35778603 | Tissue factor; from Morawitz to microparticles |
| Q24812269 | Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay |
| Q48032813 | Urate crystal induced inflammation in the rat: evidence for the combined actions of kinins, histamine and components of complement |
| Q35569193 | Variations in levels of blood clotting factors IX and X in a population of normal men: possible genetic polymorphisms |
| Q72591353 | Visual Excitation and Blood Clotting |
| Q40051514 | Vitamin K in Medical Practice: Adults |
| Q47116617 | When Blood Is Touched. |
| Q54975780 | Why Do Patients Bleed? |
| Q42909184 | Why do we want to know how factor XII levels are modulated? |
| Q37108888 | Why factor XI deficiency is a clinical concern |
| Q84912890 | [Acute ischemic stroke. New approaches to antithrombotic treatment] |
| Q83810992 | [Principles of perioperative coagulation management] |
| Q54305746 | [Principles of perioperative coagulation management]. |
| Q93621188 | [Regulation of blood coagulation] |
Search more.